Pharma and Profits
Wiley-Blackwell (Verlag)
978-1-119-88133-9 (ISBN)
This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.
Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:
- Fiscal consequences of curing hepatitis C
- mRNA vaccines and the race for a cure
- Why the government does not deserve a piece of Biopharma’s profits
- Paying for drugs whose ultimate value is unknown
- The impact of reduced revenues on R&D
This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.
John LaMattina, PhD is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. Currently a Senior Partner with PureTech Health, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (2008) and Devalued and Distrusted - Can the pharmaceutical industry restore its broken image? (2013), both published by Wiley.
Introduction
Chapter 1 The $1,000 Pill
Fiscal consequences of curing hepatitis C
Chapter 2 Enter the Payers
FDA approval does not guarantee high prices
Chapter 3 Pandemic
mRNA vaccines and the race for a cure
Chapter 4 Federal Investment in R&D
Why the government does not deserve a piece of Biopharma's profits
Chapter 5 Insulin
The true cost of a 100-year-old drug
Chapter 6 The $56,000 Alzheimer's Disease Drug
A questionable breakthrough
Chapter 7 Gene Therapies
How much is a life worth?
Chapter 8 Proving the Value of Expensive Drugs
Should we pay for drugs whose ultimate value is unknown?
Chapter 9 Generic Drugs
Built-in cost controls
Chapter 10 About Those Soaring Pharma Profits
Are they driving healthcare costs?
Chapter 11 Schemes to Lower Drug Prices
The impact of reduced revenues on R&D
Final Thoughts
| Erscheinungsdatum | 01.07.2022 |
|---|---|
| Verlagsort | Hoboken |
| Sprache | englisch |
| Gewicht | 666 g |
| Einbandart | kartoniert |
| Themenwelt | Medizin / Pharmazie ► Gesundheitswesen |
| Medizin / Pharmazie ► Medizinische Fachgebiete | |
| Medizin / Pharmazie ► Pharmazie | |
| Medizin / Pharmazie ► Studium ► 1. Studienabschnitt (Vorklinik) | |
| Naturwissenschaften ► Chemie ► Technische Chemie | |
| ISBN-10 | 1-119-88133-1 / 1119881331 |
| ISBN-13 | 978-1-119-88133-9 / 9781119881339 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
